Alnuctamab
Product Sizes
5 mg
£ POA
HY-P99430-5MG
10 mg
£ POA
HY-P99430-10MG
1 mg
£ POA
HY-P99430-1MG
About this Product
- SKU:
- HY-P99430
- Additional Names:
- EM901; CC-93269
- CAS Number:
- 2296827-07-9
- Extra Details:
- Alnuctamab (EM901) is a bispecific T-cell engager targeting BCMA and CD3; belonging to an asymmetric two-armed humanized IgG1 antibody. Alnuctamab can simultaneously bind to BCMA expressed on the surface of myeloma cells and CD3 molecules on the surface of T cells; recruiting T cells to kill tumors. Alnuctamab is used for the research of multiple myeloma. Recommend Isotype Controls: Human IgG1 kappa; Isotype Control (HY-P99001)[1][2][3].
- Molecular Weight:
- (192.13 kDa)
- Purity:
- 99.89
- References:
- [1]Danny V Jeyaraju, et al. Suppression of Myeloid Cell-Derived Proinflammatory Cytokines with Celmod Agents: Implications for CRS with T-Cell Engagers (TCEs). Blood (2022) 140 (Supplement 1): 7070–7071.|[2]Wong S W, et al. Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from a phase 1 first-in-human clinical study[J]. Blood, 2022, 140(Supplement 1): 400-402.|[3]Paiva B, et al. Synergistic antitumor activity of alnuctamab (ALNUC; BMS-986349; CC-93269), a BCMA 2+ 1 T cell engager (TCE), and celmod agents in multiple myeloma (MM) preclinical models. Blood, 2022, 140(Supplement 1): 7054-7055.
- Research Area:
- Cancer; Inflammation/Immunology
- Shipping Conditions:
- Dry Ice
- Storage Conditions:
- Store at -80[o]C for 2 years
- Type:
- Antibodies
- Pathway:
- Immunology/Inflammation
